U.S. market Closed. Opens in 1 day 9 hours 51 minutes

PFE | Pfizer Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 28.28 - 28.77
52 Week Range 25.20 - 34.62
Beta 0.47
Implied Volatility 26.73%
IV Rank 41.37%
Day's Volume 26,533,411
Average Volume 31,885,908
Shares Outstanding 5,666,700,000
Market Cap 161,840,952,000
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 1972-06-01
Valuation
Profitability
Growth
Health
P/E Ratio -62.09
Forward P/E Ratio 11.74
EPS -0.46
1YR Price Target 32.50
Dividend Yield 5.89%
Dividend Per Share 1.68
Dividend ExDate 2024-01-25
Dividend PayDate 2024-03-01
Employees 88,000
Country USA
Website PFE
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
PFE's peers: ABBV, AMGN, AZN, BIIB, BMY, GILD, JNJ, LLY, MRK, NVS, OGN
*Chart delayed
Analyzing fundamentals for PFE we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is very good and Health is weak. For more detailed analysis please see PFE Fundamentals page.

Watching at PFE technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on PFE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙